-+undefined NaN%
-+undefined NaN%
-+undefined NaN%

Wedbush Downgrades Fate Therapeutics to Neutral From Outperform Following Termination of Collaboration Agreement With Janssen, Cuts PT to $7 From $42

Wedbush Downgrades Fate Therapeutics to Neutral From Outperform Following Termination of Collaboration Agreement With Janssen, Cuts PT to $7 From $42

MT Newswires · 01/06/2023 02:57